Novartis' Piqray (alpelisib) + Fulvestrant Receive FDA's Approval for Patients with a PIK3CA Mutation in HR+/HER2- Advanced/Metastatic Breast Cancer
Shots:
- The approval is based on P-III SOLAR-1 study result assessing Piqray (alpelisib) + Fulvestrant vs Fulvestrant in 572 postmenopausal women/men in ratio (1:1) with PIK3CA-mutated HR+/HER2- advanced/m-breast cancer- following aromatase inhibitor prior treated with/without CDK4/6 inhibitor
- The P-III SOLAR-1 study result: mPFS (11.0 mos. vs 5.7mos.); ORR (35.7% vs 16.2%). Piqray & its associated companion diagnostic test from QIAGEN is approved under FDA Oncology Center of Excellence RTOR pilot program
- Piqray (alpelisib) is a PI3K inhibitor- targeting the PI3K pathway thus inhibiting the effect of PIK3CA mutations and has received FDA’s PR designation for the same indication
Ref: Novartis | Image: Anj
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com